The GNPNAT1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte cell line, engineered to disrupt the GNPNAT1 gene broadly across the cell pool without single-cell cloning. This heterogeneous knockout model enables functional interrogation of the hexosamine biosynthetic pathway (HBP) in a T-cell context, providing a versatile tool for studying glycosylation-dependent signaling and metabolic regulation. The polyclonal format preserves population-level diversity while abolishing GNPNAT1 function, making it suitable for bulk assays where clonal variation is avoided. Researchers can reliably investigate the impact of GNPNAT1 loss on T-cell biology without the constraints of monoclonal selection.
Jurkat cells are an immortalized T lymphocyte line originally derived from a patient with T-cell acute lymphoblastic leukemia (T-ALL). They serve as a widely adopted model for dissecting T-cell receptor (TCR) signaling, activation-induced apoptosis, and metabolic reprogramming in leukemic T cells. Their rapid proliferation and responsiveness to TCR engagement make them ideal for studying signaling cascades downstream of the TCR, including NF-??B and c-Myc pathways, and for evaluating drug candidates targeting T-cell malignancies. The cells?? well-characterized molecular landscape facilitates straightforward knockout validation and phenotypic readouts.
GNPNAT1 (glucosamine-phosphate N-acetyltransferase 1) catalyzes the acetylation of glucosamine-6-phosphate to N-acetylglucosamine-6-phosphate, a rate-limiting step of the HBP that generates UDP-GlcNAc, the essential donor for N- and O-linked glycosylation and for O-GlcNAc modification of nucleocytoplasmic proteins. The enzyme functions upstream of key glycosyltransferases and the O-GlcNAc cycling enzymes OGT and OGA, thereby linking nutrient flux (glucose, glutamine) to post-translational protein modification. Its activity is regulated by upstream signals including GFPT1, mTORC1, TCR engagement, and the oncogenic transcription factor MYC, and it interacts with acetyl-CoA and forms substrate-channeling complexes with GFPT1 and PGM3. Downstream, UDP-GlcNAc levels dictate the O-GlcNAcylation of signaling proteins such as NF-??B, c-Myc, and FOXO, influencing their transcriptional activity, stability, and subcellular localization.
In the Jurkat T-cell context, GNPNAT1 disruption is predicted to deplete cellular UDP-GlcNAc pools, attenuating global O-GlcNAcylation and N-linked glycosylation of critical glycoprotein receptors, thereby perturbing TCR signal transduction, proliferation, and survival. Because O-GlcNAcylation modulates NF-??B and c-Myc activity??central drivers of T-ALL and T-cell activation??loss of GNPNAT1 may impair leukemic growth and alter apoptotic thresholds. This model thus offers a valuable system for exploring the intersections of metabolism, glycosylation, and oncogenic signaling in T-cell leukemia, and for testing the role of HBP flux in immune cell function.
The knockout pool is ideal for investigating hexosamine pathway contributions to T-cell pathophysiology, including congenital disorders of glycosylation (CDG), diabetes-associated immune dysfunction, and neurodegeneration models where O-GlcNAcylation is disrupted. Typical applications encompass Western blot analysis of GNPNAT1 and O-GlcNAc levels, RT-qPCR for knockout validation, flow cytometric assessment of T-cell activation markers (e.g., CD69, CD25), UDP-GlcNAc quantification, apoptosis and proliferation assays, and glycoproteomic profiling. These polyclonal knockout cells support high-throughput screening of metabolic inhibitors targeting glycosylation and enable mechanistic dissection of O-GlcNAc-dependent signaling networks. For further details or custom inquiries, please contact Ascent Research.
